<p>沃伦·巴菲特曾说过：“波动性远非风险的同义词。” 当我们考虑一家公司的风险时，我们总是喜欢查看其债务的使用情况，因为债务过重可能导致破产。我们可以看到 <strong>Tarsus Pharmaceuticals, Inc.</strong> (NASDAQ:TARS) 确实在其业务中使用了债务。但真正的问题是，这些债务是否使公司变得风险更大。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前投资。</p>
<h2>何时债务成为问题？</h2>
<p>当企业无法轻松履行债务或其他负债时，这些债务就会变得风险很大，无论是通过自由现金流还是以有吸引力的价格筹集资本。最终，如果公司无法履行偿还债务的法律义务，股东可能会一无所获。然而，更常见（但仍然昂贵）的情况是，公司必须以低廉的股价稀释股东权益，仅仅是为了控制债务。当然，债务可以是企业的重要工具，尤其是资本密集型企业。当我们考虑一家公司的债务使用时，我们首先会将现金和债务结合起来进行分析。</p>
<h2>Tarsus Pharmaceuticals 的债务是多少？</h2>
<p>正如您在下面看到的，Tarsus Pharmaceuticals 在 2025 年 9 月的债务为 7230 万美元，与前一年大致相同。您可以点击图表以获取更多详细信息。然而，其资产负债表显示它持有 4.018 亿美元的现金，因此实际上它的净现金为 3.296 亿美元。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/650383665-debt-equity-history-analysis-1-dark-2/1768473847607?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/650383665-debt-equity-history-analysis-1-dark-2/1768473847607"/></p>
<p>NasdaqGS:TARS 债务与股本历史 2026 年 1 月 15 日</p>
<h2>Tarsus Pharmaceuticals 的资产负债表有多强？</h2>
<p>我们可以从最新的资产负债表中看到，Tarsus Pharmaceuticals 有 1.171 亿美元的负债将在一年内到期，还有 8240 万美元的负债将在之后到期。抵消这些义务的是 4.018 亿美元的现金以及价值 7430 万美元的应收账款，这些应收账款将在 12 个月内到期。因此，它可以自豪地说，其流动资产比 <em>总</em> 负债多出 2.767 亿美元。</p>
<p>这一盈余表明 Tarsus Pharmaceuticals 拥有保守的资产负债表，可能在没有太大困难的情况下消除其债务。简而言之，Tarsus Pharmaceuticals 拥有净现金，因此可以公平地说它没有沉重的债务负担！在分析债务时，资产负债表显然是重点。但未来的收益，尤其是，将决定 Tarsus Pharmaceuticals 未来维持健康资产负债表的能力。因此，如果您想看看专业人士的看法，您可能会发现这份关于分析师利润预测的免费报告很有趣。</p>
<p>查看我们对 Tarsus Pharmaceuticals 的最新分析</p>
<p>在过去一年中，Tarsus Pharmaceuticals 在 EBIT 层面上并未盈利，但其收入增长了 182%，达到了 3.66 亿美元。因此，股东们显然希望看到更多的增长！</p>
<h2>那么 Tarsus Pharmaceuticals 的风险有多大？</h2>
<p>从本质上讲，亏损的公司比那些有着长期盈利历史的公司风险更大。在过去一年中，Tarsus Pharmaceuticals 确实出现了息税前利润（EBIT）亏损。并且在同一时期，它的自由现金流出现了 6300 万美元的负流出，并记录了 8100 万美元的会计亏损。但值得庆幸的是，资产负债表上有 3.296 亿美元的现金。这笔资金意味着公司可以在当前的支出水平下继续投资于增长至少两年。对股东来说，好消息是 Tarsus Pharmaceuticals 的收入增长令人瞩目，因此它在未来几年内提升自由现金流的机会非常大。虽然亏损的公司可能存在风险，但它们在盈利前的阶段也可能快速增长。当我认为一家公司有点风险时，我觉得有必要查看内部人士是否有任何股票出售的报告。幸运的是，您可以点击这里查看我们描绘 Tarsus Pharmaceuticals 内部交易的图表。</p>
<p>归根结底，专注于没有净债务的公司往往更好。您可以访问我们特别列出的这些公司（所有公司都有盈利增长的记录）。这是免费的。</p>

TARS

<p>Tarsus Pharmaceuticals（纳斯达克代码：TARS）的资产负债表显示，其持有 4.018 亿美元现金，负债为 7230 万美元，净现金头寸为 3.296 亿美元。该公司的流动资产比总负债多出 2.767 亿美元，显示出其资产负债表较为保守。尽管在息税前利润（EBIT）层面尚未盈利，并且经历了 6300 万美元的负自由现金流，Tarsus 的收入增长达 182%，达到 3.66 亿美元。这表明未来增长的潜力，尽管由于当前的亏损状态，仍然是一项风险投资</p>

<p>Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We can see that <strong>Tarsus Pharmaceuticals, Inc.</strong> (NASDAQ:TARS) does use debt in its business. But the real question is whether this debt is making the company risky.</p>
<div class="lb-trans"><p>沃伦·巴菲特曾说过：“波动性远非风险的同义词。” 当我们考虑一家公司的风险时，我们总是喜欢查看其债务的使用情况，因为债务过重可能导致破产。我们可以看到 <strong>Tarsus Pharmaceuticals, Inc.</strong> (NASDAQ:TARS) 确实在其业务中使用了债务。但真正的问题是，这些债务是否使公司变得风险更大。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前投资。</p>
</div><h2>When Is Debt A Problem?</h2>
<div class="lb-trans"><h2>何时债务成为问题？</h2>
</div><p>Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Of course, debt can be an important tool in businesses, particularly capital heavy businesses. When we think about a company's use of debt, we first look at cash and debt together.</p>
<div class="lb-trans"><p>当企业无法轻松履行债务或其他负债时，这些债务就会变得风险很大，无论是通过自由现金流还是以有吸引力的价格筹集资本。最终，如果公司无法履行偿还债务的法律义务，股东可能会一无所获。然而，更常见（但仍然昂贵）的情况是，公司必须以低廉的股价稀释股东权益，仅仅是为了控制债务。当然，债务可以是企业的重要工具，尤其是资本密集型企业。当我们考虑一家公司的债务使用时，我们首先会将现金和债务结合起来进行分析。</p>
</div><h2>What Is Tarsus Pharmaceuticals's Debt?</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 的债务是多少？</h2>
</div><p>As you can see below, Tarsus Pharmaceuticals had US$72.3m of debt, at September 2025, which is about the same as the year before. You can click the chart for greater detail. However, its balance sheet shows it holds US$401.8m in cash, so it actually has US$329.6m net cash.</p>
<div class="lb-trans"><p>正如您在下面看到的，Tarsus Pharmaceuticals 在 2025 年 9 月的债务为 7230 万美元，与前一年大致相同。您可以点击图表以获取更多详细信息。然而，其资产负债表显示它持有 4.018 亿美元的现金，因此实际上它的净现金为 3.296 亿美元。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/650383665-debt-equity-history-analysis-1-dark-2/1768473847607" alt="" original-src="https://images.simplywall.st/asset/chart/650383665-debt-equity-history-analysis-1-dark-2/1768473847607"/></p>
<p>NasdaqGS:TARS Debt to Equity History January 15th 2026</p>
<div class="lb-trans"><p>NasdaqGS:TARS 债务与股本历史 2026 年 1 月 15 日</p>
</div><h2>How Strong Is Tarsus Pharmaceuticals' Balance Sheet?</h2>
<div class="lb-trans"><h2>Tarsus Pharmaceuticals 的资产负债表有多强？</h2>
</div><p>We can see from the most recent balance sheet that Tarsus Pharmaceuticals had liabilities of US$117.1m falling due within a year, and liabilities of US$82.4m due beyond that. Offsetting these obligations, it had cash of US$401.8m as well as receivables valued at US$74.3m due within 12 months. So it can boast US$276.7m more liquid assets than <em>total</em> liabilities.</p>
<div class="lb-trans"><p>我们可以从最新的资产负债表中看到，Tarsus Pharmaceuticals 有 1.171 亿美元的负债将在一年内到期，还有 8240 万美元的负债将在之后到期。抵消这些义务的是 4.018 亿美元的现金以及价值 7430 万美元的应收账款，这些应收账款将在 12 个月内到期。因此，它可以自豪地说，其流动资产比 <em>总</em> 负债多出 2.767 亿美元。</p>
</div><p>This surplus suggests that Tarsus Pharmaceuticals has a conservative balance sheet, and could probably eliminate its debt without much difficulty. Succinctly put, Tarsus Pharmaceuticals boasts net cash, so it's fair to say it does not have a heavy debt load! The balance sheet is clearly the area to focus on when you are analysing debt. But it is future earnings, more than anything, that will determine Tarsus Pharmaceuticals's ability to maintain a healthy balance sheet going forward. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.</p>
<div class="lb-trans"><p>这一盈余表明 Tarsus Pharmaceuticals 拥有保守的资产负债表，可能在没有太大困难的情况下消除其债务。简而言之，Tarsus Pharmaceuticals 拥有净现金，因此可以公平地说它没有沉重的债务负担！在分析债务时，资产负债表显然是重点。但未来的收益，尤其是，将决定 Tarsus Pharmaceuticals 未来维持健康资产负债表的能力。因此，如果您想看看专业人士的看法，您可能会发现这份关于分析师利润预测的免费报告很有趣。</p>
</div><p>See our latest analysis for Tarsus Pharmaceuticals</p>
<div class="lb-trans"><p>查看我们对 Tarsus Pharmaceuticals 的最新分析</p>
</div><p>In the last year Tarsus Pharmaceuticals wasn't profitable at an EBIT level, but managed to grow its revenue by 182%, to US$366m. So its pretty obvious shareholders are hoping for more growth!</p>
<div class="lb-trans"><p>在过去一年中，Tarsus Pharmaceuticals 在 EBIT 层面上并未盈利，但其收入增长了 182%，达到了 3.66 亿美元。因此，股东们显然希望看到更多的增长！</p>
</div><h2>So How Risky Is Tarsus Pharmaceuticals?</h2>
<div class="lb-trans"><h2>那么 Tarsus Pharmaceuticals 的风险有多大？</h2>
</div><p>By their very nature companies that are losing money are more risky than those with a long history of profitability. And in the last year Tarsus Pharmaceuticals had an earnings before interest and tax (EBIT) loss, truth be told. And over the same period it saw negative free cash outflow of US$63m and booked a US$81m accounting loss. But the saving grace is the US$329.6m on the balance sheet. That kitty means the company can keep spending for growth for at least two years, at current rates. The good news for shareholders is that Tarsus Pharmaceuticals has dazzling revenue growth, so there's a very good chance it can boost its free cash flow in the years to come. While unprofitable companies can be risky, they can also grow hard and fast in those pre-profit years. When I consider a company to be a bit risky, I think it is responsible to check out whether insiders have been reporting any share sales. Luckily, you can click here ito see our graphic depicting Tarsus Pharmaceuticals insider transactions.</p>
<div class="lb-trans"><p>从本质上讲，亏损的公司比那些有着长期盈利历史的公司风险更大。在过去一年中，Tarsus Pharmaceuticals 确实出现了息税前利润（EBIT）亏损。并且在同一时期，它的自由现金流出现了 6300 万美元的负流出，并记录了 8100 万美元的会计亏损。但值得庆幸的是，资产负债表上有 3.296 亿美元的现金。这笔资金意味着公司可以在当前的支出水平下继续投资于增长至少两年。对股东来说，好消息是 Tarsus Pharmaceuticals 的收入增长令人瞩目，因此它在未来几年内提升自由现金流的机会非常大。虽然亏损的公司可能存在风险，但它们在盈利前的阶段也可能快速增长。当我认为一家公司有点风险时，我觉得有必要查看内部人士是否有任何股票出售的报告。幸运的是，您可以点击这里查看我们描绘 Tarsus Pharmaceuticals 内部交易的图表。</p>
</div><p>At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.</p>
<div class="lb-trans"><p>归根结底，专注于没有净债务的公司往往更好。您可以访问我们特别列出的这些公司（所有公司都有盈利增长的记录）。这是免费的。</p>
</div>

Tarsus Pharmaceuticals (NASDAQ:TARS) 的资产负债表是否稳健？